Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Change in Cash (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Change in Cash for 11 consecutive years, with -$18.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Cash fell 176.94% to -$18.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$87.4 million, a 164.27% decrease, with the full-year FY2025 number at -$87.4 million, down 164.27% from a year prior.
  • Change in Cash was -$18.2 million for Q4 2025 at Cartesian Therapeutics, down from -$16.9 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $132.0 million in Q3 2024 to a low of -$34.0 million in Q3 2023.
  • A 5-year average of -$659500.0 and a median of -$8.8 million in 2021 define the central range for Change in Cash.
  • Biggest YoY gain for Change in Cash was 7098.83% in 2022; the steepest drop was 989.29% in 2022.
  • Cartesian Therapeutics' Change in Cash stood at -$588000.0 in 2021, then tumbled by 989.29% to -$6.4 million in 2022, then skyrocketed by 57.97% to -$2.7 million in 2023, then tumbled by 144.73% to -$6.6 million in 2024, then tumbled by 176.94% to -$18.2 million in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Change in Cash are -$18.2 million (Q4 2025), -$16.9 million (Q3 2025), and -$20.0 million (Q2 2025).